Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
100.00%
Operating Margin
99.51%
Net Margin
99.20%
Efficiency Metrics
Revenue per Expense Ratio
1.00
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
99.36%
Income Tax Rate
0.00%
EPS
3.6800000000
Balance Sheet Analysis
Current Ratio
0.00
Cash Ratio
2.27
Working Capital
$-3.15M
Debt to Equity
0.00
Debt to Assets
0.19%
Equity Ratio
98.32%
Cash Flow Analysis
Operating Cash Flow Ratio
-15.16%
Free Cash Flow Ratio
-15.16%
CapEx to Revenue
0.00%
Dividends Paid
$142.79M
Stock Buybacks
$36.27M
Total Shareholder Returns
$179.06M
Cash Position Change
-36.55%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
121.15%
Net Income
120.95%
EPS
121.51%
Operating Income
121.02%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
-6.70%
Operating Cash Flow
-123.27%
Free Cash Flow
-123.27%
Balance Sheet Health
Assets
7.25%
Debt
0.00%
Book Value per Share
9.72%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
-17.95%
Shares Outstanding
-2.57%
Long Term Trends
3Y Revenue/Share
-80.52%
5Y Revenue/Share
154.74%
3Y Dividend/Share
51.12%
5Y Dividend/Share
339.64%